Page 10«..9101112..2030..»

Category : Nanomedicine

Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region – Morning Tick

Nanomedicine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.


The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.

Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.


Scope of the Nanomedicine Market:

Nanomedicine Market by Modality:

Diagnostics TreatmentsNanomedicine Market by Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:

Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.


Chapter One: Nanomedicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanomedicine Market Competition, by Players

Chapter Four: Global Nanomedicine Market Size by Regions

Chapter Five: North America Nanomedicine Revenue by Countries

Chapter Six: Europe Nanomedicine Revenue by Countries

Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries

Chapter Eight: South America Nanomedicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries

Chapter Ten: Global Nanomedicine Market Segment by Type

Chapter Eleven: Global Nanomedicine Market Segment by Application

Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nanomedicine Market Report at:

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage



Contact: +919607065656/ +919607195908

See original here:
Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region - Morning Tick

Recommendation and review posted by Alexandra Lee Anderson

New nanomedicines for mRNA therapeutics in breast cancer and heart failure – Mirage News

TAU researcher Prof. Dan Peer, from the school of Molecular Cell Biology and Biotechnology, is one of 11 partners in the international project EXPERT that has been awarded a total of 14.9 million EUR from the EU Horizon 2020. The project is working to find efficient ways to deliver protein coding mRNA by using various nanoparticles for the treatment of breast cancer and myocardial infarction, which are two of the most pressing health challenges in European society today.

Prof. Dan Peer, Director, Laboratory of Precision NanoMedicine, School of Molecular Cell Biology and Biotechnology, George S. Wise Faculty of Life Sciences and Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University Center for Nanoscience and Nanotechnology and Tel Aviv University Cancer Biology Research Center.

It is about developing mRNA therapy for the treatment of breast cancer. Much of it involves testing different methods to improve the delivery of mRNA to cells in vivo. These methods are fundamentally based either on lipid nanoparticles (LNPs), biological nanoparticles called exosomes, or cell penetrating peptides (CPPs). In addition to this, we intend to analyze what these nanoparticles bind to in biological fluids in order to better understand what drives uptake in specific cells types.

Our lab was the first to show systemic, cell specific delivery of mRNA molecules that express therapeutic proteins in designated cells. We will further develop our ASSET platform for cell specific targeting of lipid nanoparticles to achieve improved delivery of therapeutic mRNAs and optimize formulations that enable systemic administration in different preclinical models. Part of the work will also consist of understanding how nanoparticle surfaces bind to host factors in blood and how this can affect the uptake of nanoparticles.

We will now see how these delivery methods work side by side in cell culture and animal models. The hope is then to be able to deliver an mRNA cocktail with one of the aforementioned vectors for the treatment of triple-negative breast cancer. In parallel, these vectors will also be evaluated for delivery of VEGF mRNA in the treatment of myocardial infarction.

See the rest here:
New nanomedicines for mRNA therapeutics in breast cancer and heart failure - Mirage News

Recommendation and review posted by Alexandra Lee Anderson

Covid-19 Impact On Radiocontrast Agent Market 2020: Global Industry Overview By Top Key Players Analysis And Growth Factors Up To 2025| GE Healthcare…

Radiocontrast Agent Market 2020: Latest Analysis

Chicago, United States:-TheRadiocontrast Agent market report5 Years Forecast [2020-2025]focuses on theCOVID19 Outbreak Impact analysis of key points influencing the growth of the market. The research report on the Radiocontrast Agent Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the Radiocontrast Agent market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.

Top Players of Radiocontrast Agent Market are studied:GE Healthcare (US)Bracco Imaging (Italy)Bayer HealthCare (Germany)Guerbet (France)Lantheus (US)Daiichi Sankyo (Japan)Unijules Life Sciences (India)J.B. Chemicals and Pharmaceuticals (India)Spago Nanomedicine (Sweden)Taejoon Pharm (South Korea)Jodas (India)Magnus Health (India)

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Radiocontrast Agent Market:

What Our Report Offers:

Note: Covid-19 pandemic affects most industries in the globe. Here at acquire market research we offer you comprehensive data of related industry which will help and support your business in all possible ways.Due to the pandemic of COVID-19 businesses have seen a decrease in their profits. While our intention is to help businesses regain their profits we also provide information regarding the COVID-19 virus to help our customers stay safe during the pandemic

Radiocontrast AgentSegmentation by Product

Barium-based Radiocontrast AgentIodinated Radiocontrast AgentGadolinium-based Radiocontrast AgentMicrobubble Radiocontrast AgentX-ray/Computed Tomography (CT)Magnetic Resonance Imaging (MRI)Ultrasound

Radiocontrast AgentSegmentation by Application

RadiologyInterventional RadiologyInterventional Cardiology

The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels.The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

Benefits of Buying this Market Research Report:

Our exploration specialists acutely ascertain the significant aspects of the global Radiocontrast Agent market report. It also provides an in-depth valuation in regards to the future advancements relying on the past data and present circumstance of Radiocontrast Agent market situation. In this Radiocontrast Agent report, we have investigated the principals, players in the market, geological regions, product type, and market end-client applications. The global Radiocontrast Agent report comprises of primary and secondary data which is exemplified in the form of pie outlines, Radiocontrast Agent tables, analytical figures, and reference diagrams. The Radiocontrast Agent report is presented in an efficient way that involves basic dialect, basic Radiocontrast Agent outline, agreements, and certain facts as per solace and comprehension.

Table of Contents.

Report Overview:It includes major players of the globalkeywordmarket covered in the research study, research scope, and market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the globalkeywordmarket. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the globalkeywordmarket are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the globalkeywordmarket by application, it gives a study on the consumption in the globalkeywordmarket by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the globalkeywordmarket are profiled in this section. The analysts have provided information about their recent developments in the globalkeywordmarket, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the globalkeywordmarket as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the globalkeywordmarket as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the globalkeywordmarket.

Key Findings:This section gives a quick look at the important findings of the research study.

Get Full Customize report @

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.comEmail: [emailprotected]Phone:+1 312-604-7084

Originally posted here:
Covid-19 Impact On Radiocontrast Agent Market 2020: Global Industry Overview By Top Key Players Analysis And Growth Factors Up To 2025| GE Healthcare...

Recommendation and review posted by Alexandra Lee Anderson

Translation of the long-term fundamental studies on viral DNA packaging motors into nanotechnology and nanomedicine – DocWire News

This article was originally published here

Liang C, et al. Sci China Life Sci 2020 Review.


Many years of fundamental studies on viral genome packaging motors have led to fruitful applications. The double-stranded DNA (dsDNA) viruses package their genomes into preformed protein shells via nanomotors including several elegant and meticulous coaxial modules. The motor is geared by the hexameric RNA ring. An open washer displayed as hexametric string of phi29 motor ATPase has been reported. The open washer linked into a filament as a queue with left-handed chirality along the dsDNA chain. It was found that a free 5- and 3-dsDNA end is not required for one gp16 dimer and four monomers to assemble into the hexametric washer on dsDNA. The above studies have inspired several applications in nanotechnology and nanomedicine. These applications include: (i) studies on the precision motor channels have led to their application in the single pore sensing; (ii) investigations into the hand-in-hand integration of the hexametric pRNA ring have resulted in the emergence of the new field of RNA nanotechnology; and (iii) the studies on the motor stoichiometry of homologous multi-subunits that subsequently have inspired the discovery of new methods in highly potent drug development. This review focuses on the structure and function of the viral DNA packaging motors and describes how fundamental studies inspired various applications. Given these advantages, more nanotechnological and biomedical applications using bacteriophage motor components are expected.

PMID:32617827 | DOI:10.1007/s11427-020-1752-1

Read this article:
Translation of the long-term fundamental studies on viral DNA packaging motors into nanotechnology and nanomedicine - DocWire News

Recommendation and review posted by Alexandra Lee Anderson

Nanomedicine Market Is New Business Opportunities and Investment Research Report by 2026 – 3rd Watch News


Nanomedicine is an application of nanotechnology that deals in the prevention & treatment of diseases in humans. This technology uses submicrometer-sized particles for diagnosis, treatment, and prevention of diseases. Nanomedicines are advantageous over generic drugs in several aspects such as, to reduce renal excretion, improve the ability of drugs to accumulate at pathological sites, and enhance the therapeutic index of drugs. Thus, nanomedicine is used in a wide range of applications that include aerospace materials, cosmetics, and medicine.

The global nanomedicine market was valued at $111,912 million in 2016, and is projected to reach $261,063 million by 2023, growing at a CAGR of 12.6% from 2017 to 2023. The drug delivery segment accounted for nearly two-fifths share of the global market in 2016.

Download Report Sample @

The global market is driven by increase in the development of nanotechnology-based drugs, advantages of nanomedicine in various healthcare applications, and growth in need of therapies with fewer side effects. However, long approval process and risks associated with nanomedicine (environmental impacts) restrain the market growth. In addition, growth of healthcare facilities in emerging economies is anticipated to provide numerous opportunities for the market growth.

The vaccines segment is expected to register a significant CAGR of 13.2% throughout the forecast period. The treatment segment accounted for about fourth-sevenths share in the global market in 2016, accounting for the highest share during the forecast period. This is due to the high demand for therapeutics among patient and rise in the incidence of chronic diseases.

The neurological diseases segment is expected to grow at the highest CAGR of 13.9% during the forecast period, owing to high demand for brain monitoring & treatment devices and drugs. The oncological diseases segment accounted for the highest revenue in 2016, with one-third share of the global market, and is expected to maintain its dominance throughout the forecast period.

In 2016, Asia-Pacific and LAMEA collectively accounted for about one-fourth share of the global market, and is expected to continue this trend due to increased adoption of nanomedicines, especially in China, India, and the other developing economies. In addition, rise in investments by key players in the field of nanomedicines is key driving factor of the Asia-Pacific market.

Inquire before buying @

The Major Key Players Are:

The Other Prominent Players Are:

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.


David CorreaPortland, OR, United StatesUSA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1(855)550-5975[emailprotected]Web:https://www.alliedmarketresearch.comFollow Us on LinkedIn:

Read this article:
Nanomedicine Market Is New Business Opportunities and Investment Research Report by 2026 - 3rd Watch News

Recommendation and review posted by Alexandra Lee Anderson


The recently published research report entitled Global Nanomedicine Market sheds light on critical aspects of the market like market size estimations, company and market best practices, market dynamics, market segmentation, competitive landscaping and benchmarking, opportunity analysis, economic forecasting, industry-specific technology solutions, guideline analysis, and in-depth benchmarking of vendor offerings. The report provides a clear understanding of the current and future scenarios and trends of the global Nanomedicine market. The report tracks an array of important market-related aspects which can be listed as follows; the demand and supply chain, the competitive landscape, leading industries shares, profit margin, and profiles of leading companies of the global market.

This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-depth analysis of Global Trans Resveratrol Market.


Competitive Analysis:

The section offers great insights such as market revenue and market share of the global Nanomedicine market. The report explains a competitive edge over players competitors. Leading as well as prominent players of the global market are broadly studied on the basis of key factors. The report offers a comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. The report includes the forecasts, analysis, and discussion of important industry trends, market size, market share estimates, and profiles of the leading industry players. Company profile section of players such as Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences,

Product segment analysis:

Application segment analysis: Segmentation encompasses oncology, Infectious diseases, Cardiology, Orthopedics, Other

To comprehend global Nanomedicine market dynamics in the world mainly, the worldwide market is analyzed across major global regions: North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa)

Moreover, the report elaborates different internal and external factors of the global Nanomedicine market. It uses numerous graphical presentation techniques such as graphs, tables, charts, pictures, and flowcharts. The report further focuses on market dynamics, growth drivers, developing market segments, and the market growth curve based on past, present, and future market data. The up-to-date, complete product knowledge, end-users, industry growth will drive profitability and revenue. Various important factors such as market trends, revenue growth patterns market shares, and demand and supply are included in the market research report for every industry.


The Key Highlights of The Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:[emailprotected]

View post:

Recommendation and review posted by Alexandra Lee Anderson

Nanomedicine Market Revenue Value(USD Mn), New Business Strategies and CAGR Forecast 2029 – News Monitoring

The research study Global Nanomedicine Industry provides strategic appraisal of the Nanomedicine market. Our expedition specialists acutely determine the momentous aspects of the Global Nanomedicine report. It also offers a detail valuation with respect to the future technologies relying on the historical data and present circumstance of Nanomedicine market situation. In this Nanomedicine report, we have examined the principals, manufacturers in the market, geographical regions, product type, and Nanomedicine market end-client applications. The global Nanomedicine report comprises of primary and secondary information which is epitomized in the form of pie- charts, tables, Nanomedicine analytical diagrams, and reference figures. The Nanomedicine report is presented in a competent way, that involves basic patois, basic Nanomedicine overview, agreements, and certain facts as per consolation and comprehension.

For Better Understanding, Request A Free Pdf Sample Copy Of Nanomedicine Market Here@

(***Our FREE SAMPLE COPY of the report offers a quick advent to the studies report outlook, TOC, a listing of tables and figures, an outlook to key players of the market and comprising key regions.)

Additionally, in-depth business outline, Nanomedicine market revenue study, strategies, and SWOT analysis of the top players have been provided in the report. Players in the Global Nanomedicine market are directing to vast their operations to leading regions. Further, Nanomedicine market companies are concentrate on innovation and establishing their products at competitive prices. A detail Nanomedicine supply chain study in the report will give Nanomedicine readers a better understanding.

Furthermore, the worldwide Nanomedicine market report describe segment-wise bifurcation in a way to offer the actual landscaping analogous to the market situation. The global Nanomedicine market is classified into product, application, and region with outstanding market players Pfizer Inc., Merck & Co., Ablynx NV, Nanosphere, Celgene Corporation, Abraxis BioScience, Inc., Teva Pharmaceutical Industries Limited, Inc., Abbott Laboratories, Johnson & Johnson Services, GE Healthcare Limited, Inc. and Inc..

Download Now And Browse Complete Information On The COVID 19 Impact Analysis On Nanomedicine Market:

***NOTE: As the world is experiencing the impact of Coronavirus, the MarketResearch.Biz has up to date its global Nanomedicine market research report. Our Team of Industry Researchers are Studying Covid19 and its Impact on Nanomedicine Market Growth and wherever necessary we will be considering Covid19 Footmark for Better Analysis of Market and Industries. Congenially get in Touch for More Details Information.

Market Segmentation:

Global nanomedicine market segmentation by product: Therapeutics, Regenerative medicine, In-vitro diagnostics, In-vivo diagnostics, Vaccines. Global nanomedicine market segmentation by application: Clinical Oncology, Infectious diseases, Clinical Cardiology, Orthopedics, Others

Moving ahead, the Nanomedicine market is influencing the North America market that contains (United States, Canada, and Mexico), Nanomedicine market is growing in Europe market (France, Germany, Italy, UK, and Russia), witnessed growth in the Asia Pacific region (Japan, China Korea, South East Asia and India), followed by Nanomedicine market in South America (Argentina, Columbia and Brazil), and the Middle East and Africa (UAE, Saudi Arabia, Nigeria, Egypt and South Africa).

The global Nanomedicine market reports confront the ebb and flow involved in significant market players. Several Nanomedicine movement, processes, basics, and knowledge are provided in the researching study, that ease our readers to understand the market and can differentiate with the other Nanomedicine market contenders, as well guide in taking an correct decision with regards to Nanomedicine future expectation.

Any Query? Feel Free To Inquire Here:

The data is impersonated from different sites, journals, magazines, research papers and yearly reports from Nanomedicine industries and gathered for advanced judgment. Validation of information is done by carrying out face-to-face interviews with fundamental conclusion experts and pioneers of Nanomedicine industry. Later, it is represented in form of graphs, tables and Nanomedicine market pie-diagrams.

The global Nanomedicine market has been well arranging in 15 chapters:

Chapter 1, Serves the complete assessment of the global Nanomedicine market, risk, mergers and collaboration, product classifications.

Chapter 2, Correlate with the key companies their supply-demand ratio relevant to Nanomedicine raw materials, price format, company revenue and sales.

Chapter 3, Nanomedicine market report disclose geological analysis in terms of income and sales forecasted period 2017-2026.

Chapter 4, The Nanomedicine report focuses on top driving organizations in the growing regions alongside their benefit, agreements, and market volume from 2017 to 2026.

Chapter 5,6,7, an In-sight study of the Nanomedicine market, related to top countries that give sales and revenue contribution in the market.

Chapter 8 and 9, the global Nanomedicine market explore this market through different segments, by product type, end-user applications, their market value, and growth rate.

Chapter 10 and 11, describes the Nanomedicine market circumstances over the forecast period for product type, end-client application, and regional study from 2017 to 2026.

Chapter 13,14 and 15, reveals the processed used in collecting the data, Nanomedicine market overview, different techniques used in the process of research findings, assumptions, appendix and various assets.

Get Complete Table Of Content:

Altogether, the global Nanomedicine report conducts an extensive investigation of the parent market, to know the overall of the global Nanomedicine market. Moreover, key players guiding the global Nanomedicine market over the market dimension, product scope, strategies, distinct Nanomedicine applications respecting to the market, product type along with the global market detailing and Nanomedicine advance prospects.

About Us:

MarketResearch.Biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge.We offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Contact Us:

Mr. Benni Johnson

Prudour Pvt. Ltd.

420 Lexington Avenue,

Suite 300 New York City, NY 10170,

United States

Tel: + 1-347-826-1876

Email ID:


View original post here:
Nanomedicine Market Revenue Value(USD Mn), New Business Strategies and CAGR Forecast 2029 - News Monitoring

Recommendation and review posted by Alexandra Lee Anderson

Transient stealth coating of liver sinusoidal wall by anchoring two-armed PEG for retargeting nanomedicines – Science Advances


A major critical issue in systemically administered nanomedicines is nonspecific clearance by the liver sinusoidal endothelium, causing a substantial decrease in the delivery efficiency of nanomedicines into the target tissues. Here, we addressed this issue by in situ stealth coating of liver sinusoids using linear or two-armed poly(ethylene glycol) (PEG)conjugated oligo(l-lysine) (OligoLys). PEG-OligoLys selectively attached to liver sinusoids for PEG coating, leaving the endothelium of other tissues uncoated and, thus, accessible to the nanomedicines. Furthermore, OligoLys having a two-armed PEG configuration was ultimately cleared from sinusoidal walls to the bile, while OligoLys with linear PEG persisted in the sinusoidal walls, possibly causing prolonged disturbance of liver physiological functions. Such transient and selective stealth coating of liver sinusoids by two-arm-PEG-OligoLys was effective in preventing the sinusoidal clearance of nonviral and viral gene vectors, representatives of synthetic and nature-derived nanomedicines, respectively, thereby boosting their gene transfection efficiency in the target tissues.

Nanomedicines have been widely studied for the efficient delivery of therapeutic and diagnostic agents into target tissues (16). However, nanomedicines are exposed to several clearance mechanisms, such as reticuloendothelial system (RES) uptake, after their systemic administration (79). Among these mechanisms, liver sinusoidal endothelial cells (LSECs) express numerous types of scavenger receptors for capturing a variety of nanomedicines and have high endocytic activity to clear them actively from the blood circulation (1012). The targets of LSEC-mediated clearance include both synthetic and nature-derived nanomedicines, such as viral gene vectors (13, 14), limiting their delivery efficiency to the target tissues.

To address this issue of LSEC-mediated clearance, the stealth coating of nanomedicines, e.g., by poly(ethylene glycol) (PEG), which allows nanomedicines to persist in the blood circulation for hours to days, has been widely attempted (1518). However, depending on the formulation of the nanomedicine and its drug contents, it is often difficult to obtain sufficient stealth coating to completely inhibit the clearance mechanisms without compromising nanomedicine functionality (1922). Thus, a combination of other strategies is required. The modulation of host-tissue clearance mechanisms is a promising option. For this purpose, previous studies have attempted to saturate the availability of clearing sites, e.g., by preinjecting scavenger receptor ligands, such as fucoidan (23), polyinosinic acid (poly-I) (24), and dextran sulfate (DS) (25), or decoy nanoparticles, such as polymer-albumin nanoparticles (26) and cationic liposomes (27). However, this strategy has two major problems. First, agents used for receptor saturation inhibit only specific mechanisms of sinusoidal clearance, depending on the receptors or clearance sites that they target, despite the fact that the liver sinusoid has diverse clearance pathways. Even a single nanomedicine can be recognized by several receptors (12, 28, 29), such that the simultaneous inhibition of various clearance mechanisms is preferred. Second, the receptor saturation strategy often raises safety concerns, including inflammatory responses induced by fucoidan (30) or poly-I (31) and anticoagulation associated with the administration of DS (32).

To circumvent these issues, herein we propose transient and selective stealth coating of liver sinusoidal endothelium, using precisely designed PEGylated oligocation (Fig. 1). In contrast to the previous strategy of receptor saturation, PEG coating of liver sinusoidal endothelium would be effective for the simultaneous inhibition of various clearance mechanisms. The coating should be transient and selective to the liver sinusoid to avoid toxicity concerns. This was achieved by using oligo(l-lysine) (OligoLys) conjugated with two-armed PEG at its carboxyl end (two-arm-PEG-OligoLys) for anchoring PEG to liver sinusoidal walls. The PEGylation of OligoLys allowed us to avoid the nonspecific attachment of OligoLys to the extra-liver endothelium, presumably via the steric repulsion of PEG, with preserved binding capability to liver sinusoidal endothelium, which may have high binding affinity to oligocations because of the abundance of heparan sulfate proteoglycans and scavenger receptors (11, 33, 34). The clearance behavior of the PEGylated OligoLys was successfully controlled by optimizing the PEG configuration, with two-arm-PEG-OligoLys showing transient PEG coating to the liver sinusoidal endothelium, followed by gradual biliary clearance, while the OligoLys conjugated with one-armed (linear) PEG (one-arm-PEG-OligoLys) bound to the sinusoidal endothelium persistently. Subsequently, transient and selective stealth coating of liver sinusoids by two-arm-PEG-OligoLys was found to be effective in preventing the sinusoidal clearance of nonviral and viral gene vectors, providing an increased gene transfection efficiency in their target tissues via their relocation from the liver sinusoid to the tissues.

(A) OligoLys with 20 Lys units conjugated with two linear chains of 40-kDa PEG at its carboxyl end (two-arm-PEG-OligoLys). (B) Schematic illustration of in situ stealth coating of liver sinusoidal wall. Two-arm-PEG-OligoLys selectively attaches to the sinusoidal wall to prevent the attachment of nanomedicines, such as polyplex micelle (PM) and adeno-associated virus (AAV), to the wall via stealth property of PEG. Two-arm-PEG-OligoLys is gradually cleared to the bile to avoid prolonged disturbance of liver sinusoid functions.

Short OligoLys with approximately 20 Lys units was used, as the shortening of the oligo-polycation is an effective strategy to circumvent toxicity concerns (35, 36). OligoLys was PEGylated in two different methods, using either one- or two-armed PEG. A single linear chain of 80-kDa PEG or double linear chains of 40-kDa PEG were conjugated to OligoLys at the proximal -NH2 terminus of PEG by forming a stable covalent amide bond to the distal carboxyl end of OligoLys (Fig. 2A). We selected the PEGylated OligoLys samples to have the same total Mw (weight-average molecular weight) of PEG in each molecule, i.e., 80 kDa. Total PEG Mw was set to 80 kDa for avoiding renal clearance of PEGylated OligoLys (37), which may influence its sinusoidal coating behavior. Note that each molecule of two-arm-PEG-OligoLys has two 40-kDa PEG strands, meaning that total Mw of PEG per OligoLys strand in the molecule is set at 80 kDa, and this is the same PEG Mw ratio to OligoLys as that in each of the one-arm-PEG-OligoLys molecule with a single strand of 80-kDa PEG. In this way, we can faithfully evaluate the effect of PEG configuration (linear versus two-arm branched) without an influence of total Mw of PEG fraction in each PEGylated OligoLys molecule. These PEGylated OligoLys formulations were labeled with a single molecule of Alexa Fluor 594 at the OligoLys main chain -NH2 group for the real-time fluorescence observation of their pharmacokinetic behaviors in living mice using intravital confocal laser scanning microscopy (IVCLSM).

(A) Chemical structures of one-arm-PEG-OligoLys (top, left), two-arm-PEG-OligoLys (top, right) with or without Alexa594 labeling (bottom). (B to D) Alexa594-labeled OligoLys with or without PEGylation was intravenously injected. Five minutes or 1 hour after the injection, earlobe dermis was observed using IVCLSM. (B) One-arm-PEG-OligoLys. (C) Two-arm-PEG-OligoLys. (D) Non-PEGylated OligoLys. Arrowheads, capillary walls. Two-way arrows, capillary lumen.

When observing the earlobe dermis, a representative connective tissue, after intravenous injection of one- and two-arm-PEG-OligoLys, the fluorescence intensity of the blood vessel walls was comparable with that of the lumen (Fig. 2, B and C), indicating no PEGylated OligoLys attachment to the vessel walls of the earlobe. On the contrary, non-PEGylated OligoLys with approximately 28 Lys units was aligned to the vessel walls of the earlobe as early as 5 min after injection (Fig. 2D). Thus, the attachment of OligoLys to the vessel walls of a connective tissue was successfully avoided by PEGylation of OligoLys, presumably due to stealth properties of PEG.

In sharp contrast, both one- and two-arm-PEG-OligoLys were attached to the vessel walls of the liver sinusoid within 5 min after injection (Fig. 3, A and B). Quantitative analysis revealed a much higher fluorescence intensity of the sinusoidal wall compared with the lumen (Fig. 3, C and D). This observation indicates the successful PEG coating of the liver sinusoidal wall after the injection of one- and two-arm-PEG-OligoLys. These PEGylated OligoLys formulations attached more efficiently to the blood vessel walls of the liver compared with those of the connective tissue (Fig. 2, B and C). Such selective binding of one- and two-arm-PEG-OligoLys to the liver sinusoidal wall may be attributed to the abundancy of anionic proteoglycans, such as heparan sulfate proteoglycans, present on the sinusoidal extracellular matrix, which can capture oligocations (33, 34), as well as to the high expression levels of scavenger receptors, which recognize cationic macromolecules, on sinusoidal cells (11).

(A to D) IVCLSM images after injection of Alexa594-labeled one-arm-PEG-OligoLys (A) and two-arm-PEG-OligoLys (B). Green, autofluorescence of liver parenchyma. Red, one- and two-arm-PEG-OligoLys. Presumable regions of bile canaliculi are encircled with white dotted lines. Intensity profiles of Alexa594 in the white arrows in (A) and (B) are shown in (C) and (D), respectively. (C) One-arm-PEG-OligoLys. (D) Two-arm-PEG-OligoLys. (E) Bile ducts were visualized using 5-carboxyfluorescein (CF, green). Then, Alexa594-labeled two-arm-PEG-OligoLys (magenta) was injected for observation 7 hours later. Colocalization of these two colors is observed as white or cyan (encircled by yellow dotted lines). (F) Blood circulation profiles of PEG without OligoLys, and one- and two-arm-PEG-OligoLys. n = 4. Data are shown as means SEM.

The two-arm-PEG-OligoLys fluorescence signal at the sinusoidal wall gradually decreased and became almost undetectable at 6 hours or later after injection (Fig. 3, B and D), whereas one-arm-PEG-OligoLys remained localized to the sinusoidal wall even at 9 hours after injection, with a minimal decrease in the fluorescence intensity of the sinusoidal wall during the observation period (Fig. 3, A and C). Closer observation revealed that two-arm-PEG-OligoLys was progressively accumulated to the space between the hepatocytes (encircled with dotted lines in Fig. 3B) at 3 hours or later after injection, whereas one-arm-PEG-OligoLys exhibited an almost undetectable accumulation to that space even at 9 hours after injection. On the basis of its anatomical position, the space may correspond to the bile canaliculi, which collect the bile from hepatocytes for clearance through the bile ducts. To clarify this point, a fluorescent bile tracer, 5-carboxyfluorescein (CF), was injected 5 min before two-arm-PEG-OligoLys injection. The position of two-arm-PEG-OligoLys accumulation at 7 hours after injection was colocalized with that of CF, as observed in the white or cyan pixels in Fig. 3E, which resulted from the merging of green (CF) and magenta pixels (two-arm-PEG-OligoLys). These observations indicate the gradual biliary clearance of two-arm-PEG-OligoLys.

The clearance profile of one- and two-arm-PEG-OligoLys was additionally evaluated by observing their persistence in the blood circulation. While these two groups showed comparable blood circulation profile within 1 hour after injection, obvious differences were observed at 1 hour or later after injection (Fig. 3F); the blood concentration of two-arm-PEG-OligoLys gradually decreased, while that of one-arm-PEG-OligoLys remained almost constant. The blood concentrations of one- and two-arm-PEG-OligoLys fit the two-compartment model with high R2 values, in which the polymers were administered into the central compartment and subsequently distributed into a tissue compartment (fig. S1 and table S1). These two formulations showed a comparable distribution phase half-life of around 15 min, with a comparable distribution rate constant (k12). This is consistent with the observation that both formulations similarly showed rapid binding to hepatic sinusoids. On the other hand, the elimination phase half-life of one-arm-PEG-OligoLys (13.3 hours) was much longer than that of two-arm-PEG-OligoLys (5.7 hours), which may reflect the different clearance behaviors of these two groups. The blood circulation profile of PEG without OligoLys conjugation fits the one-compartment model with high R2 values and presented a long half-life (19.8 hours). Without binding to vessel walls, this formulation may lack a distribution phase.

To obtain further mechanistic insights into the different behaviors between one- and two-arm-PEG-OligoLys, these two formulations were coinjected into mice for IVCLSM observation of their distribution in the hepatic sinusoids after labeling one-arm-PEG-OligoLys with Alexa647 (fig. S2, red) and two-arm-PEG-OligoLys with Alexa594 (green). Both formulations showed comparable levels of liver sinusoidal accumulation at 5 min to 1 hour after injection (Fig. 4 and movie S1). This observation suggests that the binding affinity of these formulations to the sinusoids is comparable. In sharp contrast, fluorescence from two-arm-PEG-OligoLys in the sinusoidal wall became weak, especially 6 hours or later after injection, presumably through biliary clearance, while a strong fluorescence signal from one-arm-PEG-OligoLys was consistently observed in the wall. Eventually, the sinusoidal walls in the images gradually became red (one-arm-PEG-OligoLys), with green (two-arm-PEG-OligoLys) appearing in the presumable location of the bile canaliculi 6 hours or later after injection. This observation is consistent with that after the single injection of each formulation, with two-arm-PEG-OligoLys still gradually cleared in the presence of one-arm-PEG-OligoLys. Thus, one-arm-PEG-OligoLys may preserve the liver functionality of biliary clearance but failed to be cleared under these conditions.

Alexa647-labeled one-arm-PEG-OligoLys (red) and Alexa594-labeled two-arm-PEG-OligoLys (green) were coinjected from the tail vein. (A) IVCLSM imaging of the liver. Presumable regions of bile canaliculi are encircled with white dotted lines. (B to D) Intensity profiles of Alexa594 and Alexa647 in the white arrows shown in (A). (B) 0.5 min, (C) 5 min, and (D) 6 hours after injection.

Toward safe usage of two-arm-PEG-OligoLys, it is important to estimate its clearance rate. For this purpose, blood clearance profile of two-arm-PEG-OligoLys was observed under its continuous intravenous infusion. In this experiment, bolus intravenous injection of two-arm-PEG-OligoLys was performed at a dose of 1250 g per mouse, which is the same as that used throughout this study. Subsequently, two-arm-PEG-OligoLys was infused at the rate reduced in a stepwise manner, to find the rate that allows the blood level of two-arm-PEG-OligoLys to be constant. Under such condition, the infusion rate of two-arm-PEG-OligoLys would be balanced with its clearance rate. The blood level of two-arm-PEG-OligoLys was constant under the infusion rate of 1200 g/hour per mouse and gradually decreased under the rate of 630 g/hour per mouse (fig. S3). This result suggests that the clearance rate of two-arm-PEG-OligoLys was approximately 1200 g/hour per mouse. This clearance may occur mainly through the biliary pathway, as two-arm-PEG-OligoLys with molecular weight over 80 kDa is unlikely to be cleared through the renal pathway. Two-arm-PEG-OligoLys accumulation to the bile canaliculi was observed in intravital observation of the liver 3 hours or later after the injection (Fig. 3B). It is also worthy to note that the biliary clearance rate of two-arm-PEG-OligoLys (1200 g/hour per mouse = 240 pmol/min per mouse) is comparable with that of cationic drugs (100 to 1000 pmol/min per mouse), as reported previously (38).

We then checked hemolysis and change in major biomarkers related to liver and kidney functions to estimate potential acute toxicity of injected polymers. Two-arm-PEG-OligoLys, as well as one-arm-PEG-OligoLys, showed no ex vivo hemolytic activity (fig. S4) and no detectable changes in plasma levels of a general tissue damage marker [lactate dehydrogenase (LDH)], liver damage markers [aspartate aminotransaminase (AST) and alanine aminotransferase (ALT)], and kidney function markers [blood urea nitrogen (BUN) and creatinine (Cre)] after in vivo administration (table S2). On the other hand, non-PEGylated OligoLys induced a substantial level of hemolysis activity ex vivo and LDH release in vivo.

Together, the above results demonstrate that the clearance behavior of the PEGylated OligoLys was successfully controlled by fine-tuning of PEG configuration. PEGylated OligoLys formulations used for the transient stealth coating of liver sinusoidal wall should simultaneously meet the following two requisites: (i) sufficient and selective stealth coating of the liver sinusoidal wall for retargeting nanomedicines and (ii) ensured clearance from the sinusoidal wall for avoiding chronic disturbance of physiological functions due to accumulation of PEG-OligoLys in the body. As shown in Figs. 2 and 3, both one- and two-arm-PEG-OligoLys attached to the sinusoidal walls selectively, meeting requisite (i). Worth noting is that two-arm-PEG-OligoLys was able to be cleared from the sinusoidal wall to the bile in several hours, while one-arm-PEG-OligoLys persisted on the wall even after 9 hours of the observation period. This result indicates that one-arm-PEG-OligoLys does not satisfy requisite (ii), which may induce safety concerns of chronic accumulation toxicity. Thus, we selected only two-arm-PEG-OligoLys for further examination devoted to evaluate redirecting efficacy of nanomedicines, demonstrating the enhanced gene expression of polyplex micelle (PM) and adeno-associated virus (AAV) in target tissues as described in the following sections.

To evaluate the feasibility of the sinusoidal PEG coating strategy, we first selected PM loading plasmid DNA (pDNA) as a model nanomedicine (39, 40). PM was prepared by mixing pDNA with one-arm-PEG-poly(l-lysine) (PLys) block copolymers with a PEG Mw of 12 kDa and a PLys polymerization degree of 44, installed with thiol moieties in 50% of the lysine residues for environment-responsive cross-linking between the cationic segments of the block copolymers. The PM was composed of a PEG shell and a core containing condensed pDNA. Disulfide cross-linking in the core stabilizes PM in extracellular environments and is selectively cleaved in intracellular reductive environments for pDNA release. According to our previous report, despite the stealth and stabilized PM formulation, a large fraction of the PM was cleared from the blood circulation within 1 hour after systemic injection, with only 23% of the dose remaining in the blood at 1 hour after injection (40). Such a moderate level of stealthiness provides us with a good platform for the application of the sinusoidal PEG coating strategy to prolong the persistence of PM in the blood circulation.

PM showed a cumulant diameter of 112 nm with a polydispersity index (PDI) of 0.15 and an almost neutral -potential of 1.5 mV, suggesting the successful formation of the core-shell structure, composed of a PEG shell and a core containing condensed pDNA. First, PM loading Cy5-labeled pDNA was intravenously injected into the mice without two-arm-PEG-OligoLys injection for IVCLSM observation of PM behavior in the liver. PM showed sinusoidal entrapment as early as 5 min after injection, despite the fact that PM was PEGylated (Fig. 5, A and C). When two-arm-PEG-OligoLys was preinjected into the mice 5 min before the PM injection, the sinusoidal entrapment of the PM was effectively prevented even at 1 hour after injection (Fig. 5, B and D). This process was more obviously visualized by labeling both of two-arm-PEG-OligoLys and PM, using Alexa594 for two-arm-PEG-OligoLys and Cy5-labeled pDNA for PM (fig. S5 and movie S2). Meanwhile, under continuous observation, PM preinjected with two-arm-PEG-OligoLys exhibited sinusoidal attachment to some extent at 3 hours after injection. This result is consistent with the gradual clearance of two-arm-PEG-OligoLys from the sinusoidal wall 3 hours after injection (Fig. 3, B and D).

Two-arm-PEG-OligoLys was intravenously injected to coat liver sinusoidal wall with PEG, followed by the intravenous injection of PM loading pDNA 5 min later. (A and B) IVCLSM imaging of PM loading Cy5-labeled pDNA (red) in the liver without PEG coating of sinusoid (A) or with the coating (B). Intensity profiles of Cy5 in the white arrows in (A) and (B) are shown in (C) and (D), respectively [(C) without coating and (D) with coating]. (E) Blood circulation profiles of PM with or without PEG coating of sinusoidal wall. n = 4. (F) PM loading Luc-expressing pDNA was injected to tumor-bearing mice with or without preinjection of two-arm-PEG-OligoLys. Luc expression in the tumor was measured 2 days after injection. n = 4. Data are shown as means SEM. Statistical analysis was performed using unpaired two-tailed Students t test.

The effect of two-arm-PEG-OligoLys preinjection on PM clearance was further evaluated by observing the blood circulation profile of PM. Without two-arm-PEG-OligoLys preinjection, PM showed two phases of decrease in its blood concentration, with a rapid drop within 1 hour after injection, followed by a gradual decrease (Fig. 5E). The marked decrease in the PM blood concentration could be attributed to its tissue distribution, including the sinusoidal entrapment, as shown in Fig. 5, A and C. Such rapid PM clearance from the blood was effectively prevented by two-arm-PEG-OligoLys preinjection, presumably via the prevention of sinusoidal PM clearance, as shown in Fig. 5, B and D.

These promising results motivated us to use our strategy for gene transfection at the tumor site, as the PM formulation used in this study provided successful outcomes in the antiangiogenic treatment of cancer in our previous reports (41, 42). PM loading luciferase (Luc) pDNA was intravenously injected into the mice bearing C26 murine colon carcinoma, 5 min after preinjection of two-arm-PEG-OligoLys. Two-arm-PEG-OligoLys preinjection resulted in a more than 10-fold increase in Luc expression efficiency in the tumor compared with the PM injection without two-arm-PEG-OligoLys preinjection (Fig. 5F). The enhanced transfection expression efficiency of PM in the tumor after two-arm-PEG-OligoLys preinjection could be attributed to the avoidance of PM sinusoidal entrapment, which may result in enhanced tumor accumulation of PM.

Last, we applied the two-arm-PEG-OligoLys preinjection approach to the administration of viral gene vectors, in which this technology is highly demanded. In particular, when organs other than the liver are targeted, sinusoidal entrapment of the vectors seriously hinders the ability of viruses to reach their target organs (14, 24), resulting in an increase in the viral dose, which then poses a safety problem. Although AAV is widely believed to be safe, high levels of toxicity have been observed in large animals after AAV administration at the dose that is required to obtain therapeutic levels of protein expression in the spine (43). Here, two-arm-PEG-OligoLys preinjection was performed 5 min before injection with AAV8 to prevent the sinusoidal clearance of AAV8 and to relocate it to the heart and skeletal muscles, which are promising target organs for the therapeutic application of AAV8 (44). Three weeks after the delivery of AAV8 expressing Luc, two-arm-PEG-OligoLys preinjection resulted in a decrease in the expression efficiency of Luc in the liver to 42% of the level observed without two-arm-PEG-OligoLys preinjection (Fig. 6A). This result suggests the successful prevention of AAV8 entrapment in the liver by the PEG coating of the sinusoidal wall using two-arm-PEG-OligoLys. Two-arm-PEG-OligoLys preinjection resulted in a significant increase in Luc expression in AAV8 target organs, a 4.3-fold increase in the heart (Fig. 6B), and a 2.3-fold increase in the skeletal muscles (Fig. 6C), respectively, presumably via the relocation of AAV8 from the liver sinusoids to these organs after sinusoidal PEG coating. This result demonstrates the effectiveness of our strategy in increasing the gene expression of viral vectors in their target organs, which will allow for a reduction in the dose of the vectors needed for gene therapy, thereby minimizing the safety concerns.

Five minutes after intravenous injection of two-arm-PEG-OligoLys for PEG coating of liver sinusoidal wall, AAV8 expressing Luc was intravenously injected. Three weeks later, Luc expression in the liver (A), heart (B), and skeletal muscle (C) was measured. n = 6. Data are shown as means SEM. Statistical analysis was performed using unpaired two-tailed Students t test.

An important feature of two-arm-PEG-OligoLys for future clinical applications is its transient binding profile to the liver sinusoidal walls with a gradual clearance to the bile, providing an advantage in terms of safety over one-arm-PEG-OligoLys, which persisted in the sinusoidal wall. To obtain mechanistic insight into the differences between one- and two-arm-PEG-OligoLys, first, the intrinsic biliary excretion profile of OligoLys without PEGylation was observed in the liver using IVCLSM. Non-PEGylated OligoLys exhibited a high accumulation to the presumable location of bile canaliculi, especially 3 hours or more after injection (fig. S6). This result indicates that OligoLys is intrinsically cleared to the bile, while this process is inhibited by single 80-kDa PEG chain conjugation to OligoLys but not by double 40-kDa PEG chain conjugation. Meanwhile, both one- and two-arm-PEG-OligoLys exhibited similar behavior in terms of their binding to the sinusoidal wall after coinjection (Fig. 4). Thus, binding affinity to the sinusoidal wall may not be a major factor for the differences between one- and two-arm-PEG-OligoLys. Two-arm-PEG-OligoLys was cleared to the bile even after coinjection with one-arm-PEG-OligoLys, indicating that one-arm-PEG-OligoLys preserves the liver functionality of biliary clearance. Even under such conditions, one-arm-PEG-OligoLys still failed to be cleared.

Although detailed molecular analyses should be performed in the future to fully explain such clearance behavior of one- and two-arm-PEG-OligoLys, it is worth proposing a possible mechanism, based on the following two hypotheses. (i) Sinusoidal walls are densely coated with PEG. (ii) Biliary clearance of PEGylated OligoLys occurs via the endocytotic pathway, especially clathrin-mediated endocytosis, which is dominant in LSECs (11). On the basis of the radius of gyration, the diameter of 40-kDa and 80-kDa PEG is around 20 and 30 nm, respectively, which is close to the typical size of clathrin-coated vesicle (50 to 200 nm) (45, 46). When cell membrane is densely coated with PEG, such large PEG chains would overlap with each other after curving of cell membrane in endocytosis, and such overlapping between PEG exclusion volume is entropically unfavorable based on a scaling theory (47, 48). Here, we estimated the effect of PEG configuration on the overlapping volume using mathematical modeling, by assuming one-arm-PEG-OligoLys as one sphere of 80-kDa PEG and two-arm-PEG-OligoLys as two spheres of 40-kDa PEG, which densely coat the plasma membrane with a hexagonal lattice structure, without overlapping. In this model, curving of cell membrane in 50- to 200 nm-sized vesicles induces overlapping of PEG chains, with 80-kDa PEG providing more than threefold larger volume of the overlap compared with 40-kDa PEG (note S1). This calculation suggests that long single PEG chain (80 kDa) may not represent a suitable cargo of endocytotic vesicles to facilitate biliary excretion, while separation of PEG chains into two segments is effective in avoiding this issue.

Such transient coating of liver sinusoidal walls with two-arm-PEG-OligoLys allowed us to relocate nonviral and viral gene vectors from the sinusoidal wall to their target tissues, thereby improving the gene transfection efficiency in the tissues. With the ability to improve nanomedicine pharmacokinetics, this approach can be used not only to enhance the effect of nanomedicines but also to reduce the dose required to obtain these effects, which is particularly important for reducing the toxicity of viral gene therapy. While clearance behavior of two-arm-PEG-OligoLys was evaluated in detail after its single bolus administration as well as under the continuous infusion for several hours (fig. S3), detailed examination of possible chronic toxicity due to polymer overloading upon multiple injections may be required in the future to translate this procedure of transient surface covering of sinusoids in clinics, because nanomedicines are administered repeatedly in many cases. Here, we faithfully focus on the configuration of PEG (linear versus two-arm branched) having the same total Mw of 80 kDa, yet optimization of total PEG Mw should also be addressed in the future for further optimal tuning of the liver sinusoidal coating to maximize the efficacy of nanomedicine therapy, with minimal influence on liver physiological functions. Our approach is versatile for combinational use with various nanomedicines, including synthetic and nature-derived nanomedicines, opening avenues for future nanotherapy and nanodiagnosis.

OligoLys with or without PEGylation was synthesized via the ring-opening polymerization (ROP) of N-trifluoroacetyl-l-lysine N-carboxyanhydride [l-Lys(TFA)-NCA, Chuo Kaseihin Co. Inc., Tokyo, Japan], as previously described for two-arm-PEG-OligoLys (49), one-arm-PEG-OligoLys (50), and non-PEGylated OligoLys (51). Briefly, for two-arm-PEG-OligoLys synthesis, two-arm--methoxy--amino-PEG [two-arm-PEG-NH2, Mn (number-average molecular weight) = 2 40 kDa, NOF Corporation, Tokyo, Japan] was used as a macroinitiator for the ROP of l-Lys(TFA)-NCA to obtain two-arm-PEG-OligoLys(TFA). The molecular weight distribution (Mw/Mn) of two-arm-PEG-OligoLys(TFA) was 1.04, according to size exclusion chromatography (SEC) (TOSOH HLC-8220; Tosoh Corp., Tokyo, Japan). The TFA groups were deprotected to obtain two-arm-PEG-OligoLys. The degree of polymerization (DP) of OligoLys in two-arm-PEG-OligoLys was 19, according to 1H nuclear magnetic resonance (NMR) spectrum (JEOL ECS 400; JEOL, Tokyo, Japan). For one-arm-PEG-OligoLys synthesis, one-arm-PEG-OligoLys(TFA) was synthesized using one-arm--methoxy--amino-PEG (one-arm-PEG-NH2, Mn = 83 kDa) as a macroinitiator of ROP of l-Lys(TFA)-NCA and exhibited Mw/Mn of 1.06 in SEC analysis. One-arm-PEG-OligoLys, obtained after the deprotection of TFA groups, showed an OligoLys DP of 21 in 1H NMR. For non-PEGylated OligoLys synthesis, OligoLys(TFA) was synthesized by ROP of l-Lys(TFA)-NCA using n-butylamine (TCI Chemicals Co. Ltd., Tokyo, Japan) as an initiator, followed by the deprotection of TFA groups to obtain OligoLys. The DP of OligoLys was 28, according to the 1H NMR spectrum. The fluorescence labeling of OligoLys with or without PEGylation was performed as previously described (49). Briefly, one- and two-arm-PEG-OligoLys and non-PEGylated OligoLys were labeled with a single molecule of Alexa dye at OligoLys at the main chain end the -NH2 group before deprotecting the TFA groups using the N-hydroxysuccinimide (NHS) ester of Alexa Fluor 594 or 647 (Thermo Fischer Scientific, Waltham, MA, USA), according to the manufacturers instructions. For injection, OligoLys with or without PEGylation, with or without fluorescence labeling, was dissolved in 10 mM Hepes buffer containing 150 mM NaCl (pH 7.3).

All animal experimental procedures were approved and conducted in compliance with the Institutional Guidelines for the Care and Use of Laboratory Animals as stated by the Animal Committee of the Innovation Center of NanoMedicine (iCONM).

All of the intravital observations in this study were performed using IVCLSM, an A1R confocal laser scanning microscope (Nikon Corp., Tokyo, Japan), connected to an upright ECLIPSE FN1 (Nikon Corp.), using the following settings. The pinhole diameter was set to obtain a 10-m optical slice. BALB/c mice (6 weeks old, female, 18 to 20 g, Charles River Laboratories Inc., Yokohama, Japan) were anesthetized with 2.5% isoflurane (Abbott Japan Co. Ltd., Tokyo, Japan) using a NARCOBIT-E Univenter 400 Anaesthesia Unit (Natsume Seisakucho Co. Ltd., Tokyo, Japan). The anesthetized mice were placed onto a temperature-controlled plate (Thermoplate; Tokai Hit Co. Ltd., Shizuoka, Japan) with the temperature set to 37C.

For the observation of blood vessels in the earlobe dermis, the earlobe was fixed using a drop of immersion oil beneath the coverslip. For the observation of the liver, the liver was surgically exposed and glued directly to the cover glass using a drop of oil. Fluorescence-labeled OligoLys with or without PEGylation was intravenously injected through a catheter inserted into the lateral tail vein slowly in approximately 30 s at the dose of 15 nmol per mouse (1.25 mg per mouse for one- and two-arm-PEG-OligoLys and 0.05 mg per mouse for non-PEGylated OligoLys). Throughout the study, the autofluorescence signal of liver parenchyma was excited using a 405-nm laser and detected using a 450/50-nm bandpass emission filter. Alexa594 was excited using a 561-nm laser and detected using a 595/50 bandpass emission filter. Alexa647 was excited using a 640-nm laser and detected using a 700/50-nm bandpass emission filter. A 40 objective lens was used for liver imaging, while a 20 objective lens was used for earlobe imaging. Images were processed using NIS-Elements software (Nikon Corp.) for the quantification of fluorescence intensity. The fluorescence intensity of each pixel in the line charts was calculated after subtracting the background fluorescence intensity, which was measured using the images obtained 10 s before sample injection.

CF diacetate (CFDA, TCI Chemicals Co. Ltd.) was intravenously injected at a dose of 0.2 mg/kg. Five minutes later, a liver image was obtained using IVCLSM, by exciting CFDA using a 488-nm laser and detecting the fluorescence using a 520/50-nm bandpass emission filter. Immediately after the CFDA imaging, two-arm-PEG-OligoLys was intravenously injected for liver imaging 7 hours later, as described in the previous section.

The blood circulation profile of fluorescence-labeled OligoLys with or without PEGylation was quantified by measuring the fluorescence intensity of the blood vessel lumen in the earlobe after injection of the samples, as described in our previous report (49). Briefly, the fluorescence intensity in the region of interest (ROI) in the vein was measured at each time point, followed by the subtraction of the background fluorescence intensity obtained 10 s before the injection. The value obtained for each time point was standardized with the maximum fluorescence intensity of the ROI during the observation period.

In the coinjection of one- and two-arm-PEG-OligoLys, a mixture of 1.25 mg per mouse of Alexa647-labeled one-arm-PEG-OligoLys and 1.25 mg per mouse of Alexa594-labeled two-arm-PEG-OligoLys was injected from the tail vein. The parenchymal autofluorescence and fluorescence signal from Alexa594 and Alexa647 was detected as described in the Intravital observation of earlobe and liver section. After subtracting the background fluorescence intensity, which was measured using the images obtained 10 s before the sample injection, the fluorescence intensity of Alexa594 and Alexa647 was standardized on the basis of the intensity of fluorescence in the blood vessel lumen at 30 s after injection, set to 100% in Fig. 4 (B to D). The attachment of one- and two-arm-PEG-OligoLys to the sinusoidal wall was almost unobservable at 30 s after injection (Fig. 4, A and B).

OligoLys with or without PEGylation was injected into the tail vein at the same dose as for intravital imaging above (1.25 mg per mouse for one- and two-arm-PEG-OligoLys and 0.05 mg per mouse for non-PEGylated OligoLys). Blood was collected from the mice 4 hours after injection to examine the plasma using a DRI-CHEM 7000i system (Fujifilm, Tokyo, Japan).

Mouse blood was centrifuged at 500g for 5 min to sediment the blood cells, followed by washing with phosphate-buffered saline (PBS; pH 7.4) twice. Red blood cells (RBCs) collected from 1 ml of the blood were suspended in 20 ml of PBS. One volume of OligoLys with or without PEGylation was added to 10 volumes of the RBC suspension. The final concentration of OligoLys with or without PEGylation was adjusted to 7.5 pM, which is the same as the calculated concentration of OligoLys in the blood when OligoLys injected at the dose used in intravital imaging above was evenly distributed in 2 ml of mouse blood. The mixture was incubated at 37C for 1 hour, followed by centrifugation at 500g for 5 min. The absorbance of the supernatant at 405 nm was measured using Microplate Reader Infinite M1000 Pro (Tecan Japan Co. Ltd., Kanagawa, Japan) to quantify the amount of hemoglobin. A mixture of one volume of Triton X-100 (20% v/v) and 10 volumes of RBC suspension was sonicated for use as a positive control (exhibits 100% activity of hemolysis). The absorbance value of each sample was compared to the value obtained for the positive control.

PEG-PLys, used for constructing PM as described in the following section, was synthesized via ROP of l-Lys(TFA)-NCA using PEG-NH2 (Mn = 12 kDa) (NOF Corporation) as a macroinitiator. The Mw/Mn of PEG-PLys(TFA) was 1.05 according to SEC. The DP of PLys in PEG-PLys was 44, based on the 1H NMR spectrum. The 1-imino-4-mercaptobutyl (IM) groups were introduced onto the side-chain -amino groups of the lysine units of the PLys segment in PEG-PLys [PEG-PLys(IM)] using 2-iminothiolane (Thermo Fischer Scientific), according to a previous report (39). The introduction ratio of IM in the total NH2 groups in the original PEG-PLys was 50%, according to the 1H NMR.

A pDNA expressing Luc, pCAG-Luc2, was constructed by cloning the Luc coding sequence of pGL4.13 vector (Promega, Madison, WI, USA) into the pCAG-GS vector (RIKEN BioResource Research Center, Tsukuba, Japan). PM was prepared from PEG-PLys(IM) and pCAG-Luc2 pDNA at [amino groups in PEG-PLys(IM) (N)] to [phosphate groups in pDNA (P)] (N/P) ratio of 2, as previously reported (39).

The dynamic light scattering (DLS) and -potential measurements were measured using a Zetasizer Nano ZS ZEN3500 (Malvern Instruments Ltd., Worcestershire, UK). For these measurements, the pDNA concentration was adjusted to 33.3 g/ml, dissolved in 10 mM Hepes buffer containing 150 mM NaCl for DLS measurement and in 10 mM Hepes buffer without NaCl addition for -potential measurements. The hydrodynamic diameter (DH) and PDI of PM were evaluated using DLS at a detection angle of 173 and a temperature of 25C using cumulant methods. The -potential was measured with electrophoretic light scattering at 37C using Smoluchowskis equation.

For injection, the pDNA concentration was adjusted to 100 g/ml with a final concentration of Hepes and NaCl of 10 and 150 mM, respectively.

For the intravital imaging of PM, pCAG-Luc2 pDNA was labeled with Cy5 using the Label IT Tracker Intracellular Nucleic Acid Localization Kit (Mirus Bio Corp., Madison, WI). PM loading Cy5-labeled pCAG-Luc2 pDNA was intravenously injected into the tail vein at the dose of 20 g per mouse 5 min after the intravenous preinjection of two-arm-PEG-OligoLys at a dose of 1.25 mg per mouse. The control mice were injected with 10 mM Hepes buffer containing 150 mM NaCl (pH 7.3) instead of two-arm-PEG-OligoLys solution before PM injection. Liver imaging and the evaluation of the blood circulation profile were performed, as described in the Intravital observation of earlobe and liver and Evaluation of blood circulation profile sections, respectively.

Murine colon adenocarcinoma 26 (C26) cells were obtained from the National Cancer Center (Tokyo, Japan) and cultured in high-glucose Dulbeccos modified Eagles medium containing 10% fetal bovine serum. C26 cells (5 106 cells per mouse) were inoculated into subcutaneous tissue in the right rear flank of BALB/c nu/nu mice (7 weeks old, female, Charles River Laboratories). Mice with tumors of approximately 100 mm3 were intravenously injected with PM loading 20 g of pCAG-Luc2 pDNA, with or without two-arm-PEG-OligoLys preinjection, as described in the previous section. Tumors were harvested 48 hours after PM injection. The extracted tumor was homogenized using Multibeads Shocker in passive lysis buffer (Promega, Madison, WI, USA), followed by a Luc assay using a Luciferase Assay System (Promega) and Lumat LB9507 (Berthold Technologies, Bad Wildbad, Germany). The luminescence intensity values were normalized to the total protein amount in the homogenates determined by the Micro BCA Protein Assay Reagent Kit (Thermo Fischer Scientific). The values were presented after subtracting the background values obtained from the tumors harvested from mice without PM injection.

BALB/c mice (6 weeks old, female, Charles River Laboratories) were intravenously injected with 1.25 mg of two-arm-PEG-OligoLys, followed by the injection of AAV8 encoding firefly Luc driven by the CMV-IVS promoter (Vector Biolabs, Malvern, PA, USA) at the dose of 2.5 1011 viral genomes per mouse, sequentially at 5-min intervals. For the control mice, 10 mM Hepes buffer containing 150 mM NaCl (pH7.3), instead of two-arm-PEG-OligoLys, was injected before the AAV injection. Three weeks after AAV8 injection, the liver, heart, and muscles from the backside were excised. The Luc assay and data were analyzed as described in the previous section for the quantification of Luc expression in the tumor tissue.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

Acknowledgments: We thank M. Kuronuma and Y. Satoh (Kawasaki Institute of Industrial Promotion) for technical assistance. Funding: This research was supported financially by the Japan Science and Technology Agency (JST) through the Center of Innovation (COI) Program [Center of Open Innovation Network for Smart Health (COINS) (grant number JPMJCE1305)], Research on the Innovative Development and the Practical Application of New Drugs for Hepatitis B from the Japan Agency for Medical Research and Development (AMED) (JP17fk0310111 to K.K.), and Grants-in-Aid for Scientific Research (B) (18 K03529 to S.U.) and for Early-Career Scientist (18 K18393 to A.D.) from the Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT). Author contributions: A.D., S.U., and K.K conceived the idea, designed all the experiments, and wrote the manuscript. A.D. performed all the experiments. K.T. helped with the IVCLSM experiments. S.A. performed the pharmacokinetic analysis. H.K. assisted with the virus experiment. S.F. helped with synthesis of the oligocations. J.L., S.O., T.A.T., X.L., K.H., and Y.M. contributed in the other experiments. K.O. discussed the experimental data. S.U. and K.K. supervised the whole project. Competing interests: K.K. is a founder and a scientific advisor of AccuRna Inc. The remaining authors declare that they have no conflict of interests. PCT patent pending: Kawasaki Institute of Industrial Promotion (K.K., S.O., S.U., K.H., A.D., and K.T). Date: 12 March 2019; serial numbers: PCT/JP2019/009919. JP patent pending: Kawasaki Institute of Industrial Promotion (K.K., S.O., S.U., K.H., and K.O). Date: 19 November 2019; serial numbers: JP2019/520319. Data and materials availability: All experimental data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested are from the authors.

Original post:
Transient stealth coating of liver sinusoidal wall by anchoring two-armed PEG for retargeting nanomedicines - Science Advances

Recommendation and review posted by Alexandra Lee Anderson

Nanomedicine Market | Covid-19 Impact | Demand, Cost Structures, Latest trends, and Forecasts to 2026 | GE Healthcare, Johnson & Johnson,…

Nanomedicine Market 2020 report share informative Covid-19 Outbreak data figures as well as important insights regarding some of the market component which is considered to be future course architects for the market. This includes factors such as market size, market share, market segmentation, significant growth drivers, market competition, different aspects impacting economic cycles in the market, demand, expected business up-downs, changing customer sentiments, key companies operating in the Nanomedicine Market, etc. In order to deliver a complete understanding of the global market, the report also shares some of the useful details regarding regional as well as significant domestic markets. The report presents a 360-degree overview and SWOT analysis of the competitive landscape of the industries.

Top Key players of Nanomedicine Market Covered In The Report:GE HealthcareJohnson & JohnsonMallinckrodt plcMerck & Co. Inc.Nanosphere Inc.Pfizer Inc.Sigma-Tau Pharmaceuticals Inc.Smith & Nephew PLCStryker CorpTeva Pharmaceutical Industries Ltd.UCB (Union chimique belge) S.A Key Market Segmentation of Nanomedicine:

Key Product type

Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery

Market by Application

Clinical CardiologyUrologyGeneticsOrthopedicsOphthalmology

Nanomedicine Market Region Mainly Focusing:

Europe Nanomedicine Market (Austria, France, Finland, Switzerland, Italy, Germany, Netherlands, Poland, Russia, Spain, Sweden, Turkey, UK), Asia-Pacific and Australia Nanomedicine Market (China, South Korea, Thailand, India, Vietnam, Malaysia, Indonesia, and Japan), The Middle East and Africa Nanomedicine Market (Saudi Arabia, South Africa, Egypt, Morocco, and Nigeria), Latin America/South America Nanomedicine Market (Brazil and Argentina), North America Nanomedicine Market (Canada, Mexico, and The USA)

Factors such as industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The report also incorporates premium quality data figures associated with financial figures of the industry including market size (in USD), expected market size growth (in percentage), sales data, revenue figures and more. This might enable readers to reach quicker decisions with data and insights at hand.

Buy Full Report Now @

(A free report data (as a form of Excel Datasheet) will also be provided upon request along with a new purchase.)

Key Highlights from Nanomedicine Market Study:

Income and Sales Estimation Historical Revenue and deals volume is displayed and supports information is triangulated with best down and base up ways to deal with figure finish market measure and to estimate conjecture numbers for key areas shrouded in the Nanomedicine report alongside arranged and very much perceived Types and end-utilize industry. Moreover, macroeconomic factor and administrative procedures are discovered explanation in Nanomedicine industry advancement and perceptive examination.

Assembling Analysis The Nanomedicine report is presently broke down concerning different types and applications. The Nanomedicine market gives a section featuring the assembling procedure examination approved by means of essential data gathered through Industry specialists and Key authorities of profiled organizations.

Competition Analysis Nanomedicine Leading players have been considered relying upon their organization profile, item portfolio, limit, item/benefit value, deals, and cost/benefit.

Demand and Supply and Effectiveness Nanomedicine report moreover gives support, Production, Consumption and (Export and Import).

Major Points Covered in Table of Contents:

Nanomedicine Market OverviewMarket Competition by ManufacturersProduction Market Share by RegionsConsumption by RegionsGlobal Nanomedicine Production, Revenue, Price Trend by TypeGlobal Nanomedicine Market Analysis by ApplicationsCompany Profiles and Key Figures in Nanomedicine BusinessNanomedicine Manufacturing Cost AnalysisMarketing Channel, Distributors, and CustomersMarket DynamicsGlobal Nanomedicine Market ForecastResearch Findings and ConclusionMethodology and Data Source

In a word, the Nanomedicine Market report provides major statistics on the state of the Nanomedicine industry with a valuable source of guidance and direction for companies and individuals interested in the market. At the end, Nanomedicine Market Report delivers a conclusion which includes Research Findings, Market Size Evaluation, Global Market Share, Consumer Needs along with Customer Preference Change, Data Source. These factors will raise the growth of the business overall.

Contact Us:

Web:www.qurateresearch.comE-mail:[emailprotected]Ph: US +13393375221

Note: In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Read more from the original source:
Nanomedicine Market | Covid-19 Impact | Demand, Cost Structures, Latest trends, and Forecasts to 2026 | GE Healthcare, Johnson & Johnson,...

Recommendation and review posted by Alexandra Lee Anderson

Assessing the Fallout From the Coronavirus Pandemic Nanomedicine to Expand Substantially Owing to Technological Innovations During 2019-2026 -…

The global Nanomedicine market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Nanomedicine market player in a comprehensive way. Further, the Nanomedicine market report emphasizes the adoption pattern of the Nanomedicine across various industries.

The Nanomedicine market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

The report on the Nanomedicine market provides a birds eye view of the current proceeding within the Nanomedicine market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Nanomedicine market and offers a clear assessment of the projected market fluctuations during the forecast period.

Request Sample Report @

market dynamics section of this report analyzes the impact of drivers and restraints on the global nanomedicine market. The impact of these drivers and restraints on the global nanomedicine market provides a view on the market growth during the course of the forecast period. Increasing research activities to improve the drug efficacy coupled with increasing government support are considered to be some of the major driving factors in this report. Moreover, few significant opportunities for the existing and new market players are detailed in this report.

Porters five forces analysis provides insights on the intensity of competition which can aid in decision making for investments in the global nanomedicine market. The market attractiveness section of this report provides a graphical representation for attractiveness of the nanomedicine market in four major regions North America, Europe, Asia-Pacific and Rest of the World, based on the market size, growth rate and industrial environment in respective regions, in 2012.

The global nanomedicine market is segmented on the basis of application and geography and the market size for each of these segments, in terms of USD billion, is provided in this report for the period 2011 2019. Market forecast for this applications and geographies is provided for the period 2013 2019, considering 2012 as the base year.

Based on the type of applications, the global nanomedicine market is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other applications. Other applications include dental, hematology, orthopedic, kidney diseases, ophthalmology, and other therapeutic and diagnostic applications of nanomedicines. Nanoparticle based medications are available globally, which are aimed at providing higher bioavilability and hence improving the efficacy of drug. There have been increasing research activities in the nanomedicine filed for neurology, cardiovascular and oncology applications to overcome the barriers in efficient drug delivery to the target site. Moreover, the global nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and Rest of the World. This section describes the nanomedicine support activities and products in respective regions, thus determining the market dynamics in these regions.

The report also provides a few recommendations for the exisitng as well as new players to increase their market share in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

Original post:
Assessing the Fallout From the Coronavirus Pandemic Nanomedicine to Expand Substantially Owing to Technological Innovations During 2019-2026 -...

Recommendation and review posted by Alexandra Lee Anderson

Page 10«..9101112..2030..»